thymosin beta-4 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-03-27. Anything still debated is marked as such rather than presented as settled.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
| Property | Value | Notes |
|---|---|---|
| Name type | Commercial trade name | Not a systematic chemical identifier |
| Parent peptide | Thymosin beta-4 | 43-residue natural peptide |
| Common fragment sequence | LKKTETQ | Maps to part of the actin-binding region |
| Molecular size class | Roughly 0.8-1.0 kDa | Depends on exact fragment and terminal modification |
| Regulatory status | Prohibited in sport | Grouped with peptide hormones in many frameworks |
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Stimulants (also called a central nervous system stimulant, psychostimulant, or colloquially an upper) are a class of psychoactive drugs that increase alertness. They are used for various purposes, such as enhancing attention, motivation, cognition, mood, and physical activity. Some stimulants occur in nature while others are synthetic. Common stimulants include caffeine, nicotine, cocaine, amphetamine, methamphetamine, methylphenidate, and modafinil. Some stimulants are subject to governmental regulation or prohibition because they can have adverse side effects including addiction, drug tolerance, drug withdrawal, psychosis, anxiety, insomnia, cardiovascular disease, and neurotoxicity. The misuse or abuse of stimulants can have serious adverse health and social consequences, such as overdose, substance dependence, crime, and violent behavior. Stimulants increase activity in the sympathetic nervous system. They often increase synaptic concentrations of excitatory neurotransmitters, particularly norepinephrine and dopamine. Other stimulants work by binding to the receptors of excitatory neurotransmitters (e.g., nicotine) or by blocking the activity of endogenous agents that promote sleep (e.g., caffeine). Stimulants can affect various functions, including arousal, attention, the reward system, learning, memory, and emotion. Effects range from mild stimulation to euphoria, depending on the specific drug, dose, route of administration, and inter-individual characteristics. Stimulants have a long history of use, both for medical and non-medical purposes.
JTT (1992). Published in the same year as BLOSOM, it also performs clustering and uses an implicit model. This may help reduce the systematic error from maximum parismony (MP), but also wastes sequence information. VTML (2001), a PAM-like matrix based on the alignments in the SYSTERS database, iteratively improved using a maximum likelihood estimator starting from the 1970s Dayhoff PAM model. WAG (Wheelan And Goldman, 2001) uses a maximum likelihood estimating procedure instead of any form of MP over a "BRKALN" dataset. The substitution scores are calculated based on the likelihood of a change considering multiple tree topologies derived using neighbor-joining. The scores correspond to a substitution model which includes also amino-acid stationary frequencies and a scaling factor in the similarity scoring. There are two versions of the matrix: WAG matrix based on the assumption of the same amino-acid stationary frequencies across all the compared protein and WAG* matrix with different frequencies for each of included protein families. PMB (Probability Matrix from Blocks, 2003), a set of "true" substitution frequencies estimated from the observed frequencies of BLOSUM, taking into account the possibility of a later substitution masking a previous one. It thus creates a evolutionary model where the distances have theoretical meaning (BLOSUM does not have this feature, unlike PAM, WAG, and most other later matrices, and hence is not recommended for phylogeny by IQ-TREE). LG (2008), which uses a larger dataset (Pfam-based) than WAG.
Britain had expected a swift victory against a mostly unmilitarised and predominantly agricultural-based opponent. Britain was the world's most technologically advanced military. The results caused many both domestically and internationally to question the dominance of the British Empire, especially as nations like the US, Germany, and Japan had become major powers.
== Low-level exposure == As the energy of radio frequency waves and microwaves is insufficient to directly disrupt individual chemical bonds in small or stable molecules, the effects are considered limited to thermal. Energy densities that are not sufficient to overheat the tissues are not shown to cause lasting damage. To clarify, the deep-red lightbulb in a black-and-white photographic darkroom produces a higher-energy form of radiation than microwaves. Like a microwave, this lightbulb can burn, particularly if touched, but the burn is only possible due to too much heat. A study of 20,000 radar technicians of the US Navy, who were chronically exposed to high levels of microwave radiation, did not detect increased incidence of cancer. Recent epidemiologic evidence also led to the consensus that exposure to electromagnetic fields, e.g. along power lines, did not raise incidence of leukemia or other cancers.
Sources: en.wikipedia.org
At the time of its discovery, sanatoriums for the isolation of tuberculosis-infected people were a ubiquitous feature of cities in developed countries, with 50% dying within 5 years of admission. Although Merck's agreement with Rutgers gave it exclusive rights to streptomycin, at Waksman's request the company renegotiated the agreement, returning the rights to the university in exchange for a royalty. The university then set up non-exclusive licenses with seven companies to ensure a reliable supply of the antibiotic.
=== Protein degradation === Arginine phosphorylation by McsB kinase marks proteins for degradation by a Clp protease. The arginine phosphorylation system, which is widely distributed across Gram-positive bacteria, appears to be functionally analogous to the eukaryotic ubiquitin–proteasome system.
All polyamides are made by the formation of an amide function to link two molecules of monomer together. The monomers can be amides themselves (usually in the form of a cyclic lactam such as caprolactam), α,ω-amino acids or a stoichiometric mixture of a diamine and a diacid. Both these kinds of precursors give a homopolymer. Polyamides are easily copolymerized, and thus many mixtures of monomers are possible which can in turn lead to many copolymers. Additionally many nylon polymers are miscible with one another allowing the creation of blends.
Sources: en.wikipedia.org
James Wallace Jorgenson is an American academic who previously held the position of William Rand Kenan Jr. Distinguished Professor of Chemistry at UNC-Chapel Hill. He is best known for his work developing capillary zone electrophoresis, and is a member of the American Academy of Arts and Sciences.
=== First Trump administration (2017–2021) === On August 13, 2018, Section 1051 of the Fiscal Year 2019 John S. McCain National Defense Authorization Act (P.L. 115-232) established the National Security Commission on Artificial Intelligence "to consider the methods and means necessary to advance the development of artificial intelligence, machine learning, and associated technologies to comprehensively address the national security and defense needs of the United States." Steering on regulating security-related AI is provided by the National Security Commission on Artificial Intelligence. The Artificial Intelligence Initiative Act (S.1558) is a proposed bill that would establish a federal initiative designed to accelerate research and development on AI for, inter alia, the economic and national security of the United States. On January 7, 2019, following an Executive Order on Maintaining American Leadership in Artificial Intelligence, the White House's Office of Science and Technology Policy released a draft Guidance for Regulation of Artificial Intelligence Applications, which includes ten principles for United States agencies when deciding whether and how to regulate AI. In response, the National Institute of Standards and Technology (NIST) released a position paper, and the Defense Innovation Board issued recommendations on the ethical use of AI. A year later, the administration called for comments on regulation in another draft of its Guidance for Regulation of Artificial Intelligence Applications.
An alternative approach to the identification and quantification of patient samples is through the use of mass spectrometry. This approach offers excellent precision and sensitivity in the identification, characterization and quantification of metabolites in multiple patient sample types, such as blood and urine. The mass spectrometry (MS) approach is typically coupled to gas chromatography (GC), in GC-MS or liquid chromatography (LC), in LC-MS, which aid in initially separating out the metabolite components within complex sample mixtures, and can allow for the isolation of particular metabolite subsets for analysis. GC-MS can provide relatively precise quantification of metabolites, as well as chemical structural information that can be compared to pre-existing chemical libraries. GC-MS can be conducted in a relatively high-throughput manner (greater than 100 samples per day) with greater detection sensitivity than NMR analysis. A limitation of GC-MS for this application, however, is that processed metabolite components must be readily volatilized for sample processing. LC-MS initially separates out the components of a sample mixture based on properties such as hydrophobicity, before processing them for identification and quantification by mass spectrometry (MS). Overall, LC-MS is an extremely flexible method for processing most compound types in a somewhat high-throughput manner (20-100 samples a day), also with greater sensitivity than NMR analysis. For both GC-MS and LC-MS there are limitations in the reproducibility of metabolite quantification.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.
Published work usually examines actin binding, cell migration and tissue repair endpoints in cell and animal models. Findings are generally described as preliminary, and controlled human data remain limited.
Because TB-500 is a trade name rather than a chemical identifier, different vendors and papers may attach it to different fragment lengths. Checking the stated sequence is the practical way to resolve the ambiguity.
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.